Bio-Techne (TECH) Form 4 BIO-TECHNE / James Hippel ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hippel James

(Last) (First) (Middle)

614 MCKINLEY PLACE N.E.

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2019		M		35,000	A	$86.25	39,382	D
Common Stock	05/01/2019		S		35,000	D	$203.0766(1)	4,382	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$86.25	05/01/2019		M		10,000		06/30/2015	04/01/2021	Common Stock	10,000	$0.00	0.00	D
Stock Options (Right to buy)	$86.25	05/01/2019		M		25,000		04/01/2018	04/01/2021	Common Stock	25,000	$0.00	0.00	D
Restricted Stock Units	(2)							(3)	(3)	Common Stock	3,383		3,383	D
Restricted Stock Units	(2)							(4)	(4)	Common Stock	4,438		4,438	D
Restricted Stock Units	(2)							(5)	(5)	Common Stock	4,925		4,925	D
Stock Option (Right to Buy)	$106.59							(6)	08/18/2023	Common Stock	30,400		30,400	D
Stock Option (Right to Buy)	$94.35							(7)	08/12/2021	Common Stock	35,000		35,000	D
Stock Options (Right to buy)	$177.32							(8)	08/08/2025	Common Stock	24,089		24,089	D
Stock Options (Right to buy)	$177.32							(3)	08/08/2025	Common Stock	18,066		18,066	D
Stock Options (Right to buy)	$125.05							(4)	08/09/2024	Common Stock	24,460		24,460	D
Stock Options (Right to buy)	$125.05							(9)	08/09/2024	Common Stock	32,613		32,613	D
Stock Options (Right to buy)	$108.49							(10)	08/07/2022	Common Stock	25,000		25,000	D
Stock Options (Right to buy)	$106.59							(11)	08/18/2023	Common Stock	40,533		40,533	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.28 to $205.38, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

3. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

4. Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

5. Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)

6. Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

7. 8,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

8. Vests 6,023 shares on 8/8/2019 and 6,022 shares each on 8/8/2020, 8/8/2021 and 8/8/20202

9. Vests 8,153 shares each on 8/19/2018, 8/9/2019, 8/9/2020 and 8,154 on 8/9/2021

10. 6,250 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

11. Vests 10,134 shares on 8/18/17, and 10,133 shares on each of 8/18/18, 8/18/19 and 8/18/20.

Remarks:

	/s/ Brenda S. Furlow, attorney in fact for James Hippel pursuant to Power of Attorney previously filed	05/02/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.